JP2017524735A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524735A5 JP2017524735A5 JP2017522324A JP2017522324A JP2017524735A5 JP 2017524735 A5 JP2017524735 A5 JP 2017524735A5 JP 2017522324 A JP2017522324 A JP 2017522324A JP 2017522324 A JP2017522324 A JP 2017522324A JP 2017524735 A5 JP2017524735 A5 JP 2017524735A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- composition
- acceptable salt
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 5
- 102000003964 Histone deacetylase Human genes 0.000 claims 5
- 108090000353 Histone deacetylase Proteins 0.000 claims 5
- 229960002756 azacitidine Drugs 0.000 claims 5
- 208000032839 leukemia Diseases 0.000 claims 5
- 102100022537 Histone deacetylase 6 Human genes 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 108010023925 Histone Deacetylase 6 Proteins 0.000 claims 2
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 claims 2
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000003833 cell viability Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 *N(CCCCCCC(NO)=O)C(c1cnc(N(*)/C2=C/C/C=C/C=C/C2)nc1)=O Chemical compound *N(CCCCCCC(NO)=O)C(c1cnc(N(*)/C2=C/C/C=C/C=C/C2)nc1)=O 0.000 description 3
- VLIUIBXPEDFJRF-UHFFFAOYSA-N ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O)=O Chemical compound ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O)=O VLIUIBXPEDFJRF-UHFFFAOYSA-N 0.000 description 3
- QGZYDVAGYRLSKP-UHFFFAOYSA-N ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c2ccccc2)nc1)=O)=O Chemical compound ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c2ccccc2)nc1)=O)=O QGZYDVAGYRLSKP-UHFFFAOYSA-N 0.000 description 3
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462021473P | 2014-07-07 | 2014-07-07 | |
| US62/021,473 | 2014-07-07 | ||
| US201462061233P | 2014-10-08 | 2014-10-08 | |
| US62/061,233 | 2014-10-08 | ||
| US201562147218P | 2015-04-14 | 2015-04-14 | |
| US62/147,218 | 2015-04-14 | ||
| PCT/US2015/039225 WO2016007423A1 (en) | 2014-07-07 | 2015-07-06 | Treatment of leukemia with histone deacetylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524735A JP2017524735A (ja) | 2017-08-31 |
| JP2017524735A5 true JP2017524735A5 (enExample) | 2018-08-02 |
| JP6952602B2 JP6952602B2 (ja) | 2021-10-20 |
Family
ID=55064739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522324A Active JP6952602B2 (ja) | 2014-07-07 | 2015-07-06 | ヒストンデアセチラーゼ阻害剤による白血病の治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9833466B2 (enExample) |
| EP (1) | EP3166603B1 (enExample) |
| JP (1) | JP6952602B2 (enExample) |
| KR (1) | KR20170044097A (enExample) |
| CN (1) | CN107205988A (enExample) |
| AU (1) | AU2015288060A1 (enExample) |
| BR (1) | BR112017000301A2 (enExample) |
| CA (1) | CA2954522A1 (enExample) |
| EA (1) | EA201790142A1 (enExample) |
| IL (1) | IL249935A0 (enExample) |
| MX (1) | MX2017000307A (enExample) |
| SG (1) | SG11201700094TA (enExample) |
| WO (1) | WO2016007423A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201500444TA (en) * | 2010-01-22 | 2015-03-30 | Acetylon Pharmaceuticals Inc | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
| WO2013158984A1 (en) | 2012-04-19 | 2013-10-24 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| EP3054952B1 (en) | 2013-10-08 | 2022-10-26 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer |
| WO2015061684A1 (en) | 2013-10-24 | 2015-04-30 | Mayo Foundation For Medical Education And Research | Treatment of polycystic diseases with an hdac6 inhibitor |
| CN105939716A (zh) | 2013-12-03 | 2016-09-14 | 埃斯泰隆制药公司 | 组蛋白脱乙酰基酶抑制剂和免疫调节药物的组合 |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
| BR112017012504A2 (pt) | 2014-12-12 | 2018-01-09 | Acetylon Pharmaceuticals, Inc. | derivados de piperidina como inibidores de hdac1/2 |
| US11249071B2 (en) * | 2015-04-24 | 2022-02-15 | California Institute Of Technology | Reactivation of x chromosome genes |
| CN107922352B (zh) | 2015-06-08 | 2021-08-06 | 埃斯泰隆制药公司 | 制备蛋白质脱乙酰酶抑制剂的方法 |
| US10464906B2 (en) | 2015-06-08 | 2019-11-05 | Acetylon Pharmaceuticals, Inc. | Crystalline forms of a histone deacetylase inhibitor |
| WO2017184774A1 (en) | 2016-04-19 | 2017-10-26 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia |
| WO2017214565A1 (en) * | 2016-06-09 | 2017-12-14 | Dana-Farber Cancer Institute, Inc., | Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors |
| US11324744B2 (en) | 2016-08-08 | 2022-05-10 | Acetylon Pharmaceuticals Inc. | Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies |
| WO2018081661A1 (en) | 2016-10-27 | 2018-05-03 | California Institute Of Technology | Hdac inhibitor compositions for reactivation of the x chromosome |
| EP3544600A4 (en) | 2016-11-23 | 2020-06-17 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereof |
| CN106810460A (zh) * | 2016-12-30 | 2017-06-09 | 苏州诚和医药化学有限公司 | 一种4‑[2‑(二甲基氨基)乙氧基]苄胺的制备方法 |
| US11709164B2 (en) | 2017-10-26 | 2023-07-25 | National University Of Singapore | Approach for universal monitoring of minimal residual disease in acute myeloid leukemia |
| JP7021503B2 (ja) * | 2017-11-02 | 2022-02-17 | 三菱瓦斯化学株式会社 | 脂肪族ジアミンの製造方法 |
| CN116421598B (zh) * | 2022-01-11 | 2024-08-30 | 苏州亚盛药业有限公司 | 用于治疗aml-mrc和mds的方法 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3549633A (en) | 1968-11-20 | 1970-12-22 | Merck & Co Inc | Process for preparation of 1-h-imidazo (4,5-b)pyrazin-2-ones |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| CA2404002A1 (en) | 2000-03-24 | 2001-09-27 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| WO2002074298A1 (en) | 2001-03-21 | 2002-09-26 | Ono Pharmaceutical Co., Ltd. | Il-6 production inhibitors |
| US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| HUP0402330A3 (en) | 2001-11-01 | 2010-03-29 | Janssen Pharmaceutica Nv | Amide derivatives as glycogen synthase kinase 3-beta inhibitors, process for producing them, pharmaceutical compositions containing them and use thereof |
| MY140390A (en) | 2002-03-13 | 2009-12-31 | Janssen Pharmaceutica Nv | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
| PL212089B1 (pl) | 2002-03-13 | 2012-08-31 | Janssen Pharmaceutica Nv | Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| US7375228B2 (en) | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| AU2004261373B8 (en) | 2003-07-24 | 2010-11-04 | Basf Se | 2-substituted pyrimidines |
| TWI349664B (en) | 2003-09-22 | 2011-10-01 | S Bio Pte Ltd | Benzimidazole derivatives: preparation and pharmaceutical applications |
| JP4809228B2 (ja) | 2003-09-24 | 2011-11-09 | メチルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
| JP4993374B2 (ja) | 2004-04-05 | 2012-08-08 | メルク エイチディーエーシー リサーチ エルエルシー | ヒストン脱アセチル化酵素インヒビタープロドラッグ |
| EP3354265A1 (en) | 2005-03-22 | 2018-08-01 | President and Fellows of Harvard College | Treatment of solid tumors |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| US20070155730A1 (en) | 2005-08-26 | 2007-07-05 | Methylgene, Inc. | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase |
| ES2384182T3 (es) | 2005-11-01 | 2012-07-02 | Sumitomo Chemical Company, Limited | Proceso para la producción de 6,6-dimetil-3-oxabiciclo[3,1,0]hexan-2-ona |
| AU2007213018A1 (en) | 2006-02-07 | 2007-08-16 | Astellas Pharma Inc. | N-hydroxyacrylamide compounds |
| CA2642273C (en) | 2006-02-14 | 2016-09-20 | President And Fellows Of Harvard College | Bifunctional histone deacetylase inhibitors |
| WO2007118137A1 (en) | 2006-04-07 | 2007-10-18 | Methylgene Inc. | Benzamide derivatives as inhibitors of histone deacetylase |
| WO2007127137A2 (en) | 2006-04-26 | 2007-11-08 | Merck & Co., Inc. | Disubstituted aniline compounds |
| US8304451B2 (en) | 2006-05-03 | 2012-11-06 | President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
| US20100278782A1 (en) | 2006-06-12 | 2010-11-04 | Vrije Universiteit Brussel | Differentiation of rat liver epithelial cells into hepatocyte-like cells |
| ES2288802B1 (es) | 2006-07-07 | 2008-12-16 | Universidad De Granada | Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas. |
| CA2662580C (en) | 2006-09-11 | 2013-05-21 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| US8399452B2 (en) | 2006-10-28 | 2013-03-19 | Methylgene Inc. | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors |
| EP2077999B1 (en) | 2006-10-30 | 2014-07-30 | Chroma Therapeutics Limited | Hydroxamates as inhibitors of histone deacetylase |
| US8518979B2 (en) | 2007-02-21 | 2013-08-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Alpha-halo- and alpha-alkyl-cyclopropylcarboxy compounds and uses thereof |
| JP2010120852A (ja) | 2007-03-09 | 2010-06-03 | Daiichi Sankyo Co Ltd | 新規なジアミド誘導体 |
| US20090124631A1 (en) | 2007-09-14 | 2009-05-14 | Zuomei Li | Combination Therapy |
| CN101951930A (zh) | 2008-02-19 | 2011-01-19 | 阿奈斯特药品株式会社 | 对身体功能的恢复有用的口服或经肠组合物 |
| WO2009137503A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Hdac inhibitors and uses thereof |
| US20110288070A1 (en) | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| NZ602832A (en) | 2008-07-14 | 2014-04-30 | Gilead Sciences Inc | Fused heterocyclic hdac inhibitor compounds |
| AU2009274549B2 (en) | 2008-07-23 | 2014-05-01 | Dana-Farber Cancer Institute, Inc. | Deacetylase inhibitors and uses thereof |
| RS54230B1 (sr) | 2009-01-08 | 2015-12-31 | Curis Inc. | Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink |
| EP2429987A4 (en) | 2009-05-15 | 2012-10-03 | Korea Res Inst Chem Tech | AMIDE COMPOUND, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
| JP5838157B2 (ja) | 2009-07-22 | 2015-12-24 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ | Ｈｄａｃ阻害剤およびそれを用いる治療法 |
| WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
| EP2638009A4 (en) | 2010-01-08 | 2014-06-11 | Harvard College | FLUORINATED HDAC HEMMER AND USES THEREOF |
| SG10201500444TA (en) | 2010-01-22 | 2015-03-30 | Acetylon Pharmaceuticals Inc | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
| EP2571352A4 (en) | 2010-05-21 | 2014-09-17 | Sloan Kettering Inst Cancer | SELECTIVE HDAC HEMMER |
| WO2012018499A2 (en) | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| ES2568260T3 (es) * | 2010-11-16 | 2016-04-28 | Acetylon Pharmaceuticals, Inc. | Compuestos de pirimidin hidroxi amida como inhibidores de proteína desacetilasa y métodos de uso de los mismos |
| US8404738B2 (en) | 2011-01-21 | 2013-03-26 | Hoffmann-La Roche Inc. | 4-amino-N-hydroxy-benzamides for the treatment of cancer |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| JP6169076B2 (ja) * | 2011-07-20 | 2017-07-26 | ザ ジェネラル ホスピタル コーポレイション | 骨疾患の処置のためのヒストン脱アセチル化酵素６選択的阻害剤 |
| WO2013158984A1 (en) * | 2012-04-19 | 2013-10-24 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| US9145412B2 (en) * | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| WO2014121062A1 (en) | 2013-02-01 | 2014-08-07 | Acetylon Pharmaceuticals, Inc. | Selective hdac3 inhibitors |
| US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
| EP3004141A4 (en) | 2013-06-03 | 2017-05-31 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase ( hdac) biomarkers in multiple myeloma |
| EP3054952B1 (en) | 2013-10-08 | 2022-10-26 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer |
| EP3055299B1 (en) | 2013-10-10 | 2021-01-06 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| JP2016536354A (ja) | 2013-10-10 | 2016-11-24 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との組み合わせ |
| ES2818933T3 (es) | 2013-10-10 | 2021-04-14 | Acetylon Pharmaceuticals Inc | Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin |
| CN105722507A (zh) | 2013-10-11 | 2016-06-29 | 埃斯泰隆制药公司 | 组蛋白脱乙酰酶抑制剂与免疫调节药物的组合 |
| CN105939716A (zh) | 2013-12-03 | 2016-09-14 | 埃斯泰隆制药公司 | 组蛋白脱乙酰基酶抑制剂和免疫调节药物的组合 |
| ES2936812T3 (es) | 2013-12-20 | 2023-03-22 | Acetylon Pharmaceuticals Inc | Biomarcadores de histona desacetilasa 6 (HDAC6) en mieloma múltiple |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
-
2015
- 2015-07-06 CA CA2954522A patent/CA2954522A1/en not_active Abandoned
- 2015-07-06 JP JP2017522324A patent/JP6952602B2/ja active Active
- 2015-07-06 CN CN201580047830.2A patent/CN107205988A/zh active Pending
- 2015-07-06 BR BR112017000301A patent/BR112017000301A2/pt not_active Application Discontinuation
- 2015-07-06 KR KR1020177003321A patent/KR20170044097A/ko not_active Withdrawn
- 2015-07-06 US US14/792,046 patent/US9833466B2/en not_active Expired - Fee Related
- 2015-07-06 EA EA201790142A patent/EA201790142A1/ru unknown
- 2015-07-06 AU AU2015288060A patent/AU2015288060A1/en not_active Abandoned
- 2015-07-06 MX MX2017000307A patent/MX2017000307A/es unknown
- 2015-07-06 SG SG11201700094TA patent/SG11201700094TA/en unknown
- 2015-07-06 WO PCT/US2015/039225 patent/WO2016007423A1/en not_active Ceased
- 2015-07-06 EP EP15818585.0A patent/EP3166603B1/en active Active
-
2017
- 2017-01-05 IL IL249935A patent/IL249935A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524735A5 (enExample) | ||
| JP2016532667A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JP2016501221A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2014507446A5 (enExample) | ||
| JP2016521119A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2013032389A5 (enExample) | ||
| FI3256218T3 (fi) | Kdm1a-estäjät sairauksien hoidossa | |
| JP2016518337A5 (enExample) | ||
| JP2016508134A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2017518334A5 (enExample) | ||
| JP2014521735A5 (enExample) | ||
| JP2017537066A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| JP2015518055A5 (enExample) | ||
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| JP2014508804A5 (enExample) | ||
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| JP2015516419A5 (enExample) |